JP2013542256A5 - - Google Patents

Info

Publication number

JP2013542256A5

JP2013542256A5 JP2013538820A JP2013538820A JP2013542256A5 JP 2013542256 A5 JP2013542256 A5 JP 2013542256A5 JP 2013538820 A JP2013538820 A JP 2013538820A JP 2013538820 A JP2013538820 A JP 2013538820A JP 2013542256 A5 JP2013542256 A5 JP 2013542256A5

Authority

JP

Japan

Prior art keywords

composition

compound

variant

item

pharmaceutically acceptable

Prior art date

2011-11-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 26
• 239000000203 mixture Substances 0.000 claims description 25
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 18
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 18
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 18
• 230000003213 activating effect Effects 0.000 claims description 15
• 150000003839 salts Chemical class 0.000 claims description 13
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 125000000217 alkyl group Chemical group 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
• 239000003814 drug Substances 0.000 claims description 4
• 125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 230000037430 deletion Effects 0.000 claims description 3
• 238000012217 deletion Methods 0.000 claims description 3
• 230000001404 mediated effect Effects 0.000 claims description 3
• 230000035772 mutation Effects 0.000 claims description 3
• 239000002671 adjuvant Substances 0.000 claims description 2
• 239000002246 antineoplastic agent Substances 0.000 claims description 2
• 229940127089 cytotoxic agent Drugs 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000002401 inhibitory effect Effects 0.000 claims description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
• 239000003981 vehicle Substances 0.000 claims description 2
• 230000004913 activation Effects 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 238000000034 method Methods 0.000 description 22
• 239000012472 biological sample Substances 0.000 description 2
• 0 CC(C)*(C)(C)c1cc(OC)c(C)cc1 Chemical compound CC(C)*(C)(C)c1cc(OC)c(C)cc1 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1